```html

Altitudinal Visual Loss

What is Altitudinal visual loss?

Altitudinal visual loss describes a loss of vision that involves either the upper (superior) or lower (inferior) half of the visual field in one eye, or occasionally both eyes. The term “altitudinal” refers to altitude or “height” – the defect follows a horizontal line across the retina, sparing the opposite half. This pattern is distinct from arcuate or sector‑shaped defects and often points toward diseases that affect the optic nerve head or retinal blood supply.

Because the optic nerve fibers that correspond to the upper and lower visual fields are arranged in a predictable manner, an altitudinal defect can give clinicians clues about the underlying pathology. Prompt recognition is essential, as several causes can threaten permanent vision loss if untreated.

Common Causes

Altitudinal visual field loss is not a disease itself but a sign that may arise from a variety of ocular or systemic conditions. The most frequent causes include:

• Anterior Ischemic Optic Neuropathy (AION) – especially the non‑arteritic form (NA‑AION) caused by small‑vessel infarction of the optic nerve head.
• Ischemic Optic Neuropathy due to Giant Cell Arteritis – the arteritic (AAION) variant that can produce rapidly progressive altitudinal loss.
• Posterior Circulation Stroke – infarction in the occipital lobe or optic radiations can create a hemianopic pattern that may mimic altitudinal loss.
• Optic Nerve Sheath Meningioma – compressive lesions at the optic canal often affect the inferior or superior fibers.
• Anterior Optic Nerve Glioma – more common in children; may produce a segmental field defect.
• Retinal Vascular Occlusion – especially a branch retinal artery occlusion that follows a horizontal watershed zone.
• Papilledema with Severe Swelling – can cause transient altitudinal loss due to axonal compression.
• Traumatic Optic Neuropathy – blunt or penetrating head injuries that damage the optic nerve fibers selectively.
• Optic Neuritis (Atypical) – though classically central, some cases present with altitudinal defects, especially when associated with demyelinating disease.
• Systemic Vasculopathies – such as systemic lupus erythematosus or polyarteritis nodosa, which may cause small‑vessel ischemia of the optic nerve.

These conditions account for the majority of altitudinal visual loss cases reported in ophthalmology and neuro‑ophthalmology literature (Mayo Clinic, 2022; NIH Eye Institute, 2023).

Associated Symptoms

Patients rarely experience altitudinal loss in isolation. Other visual or systemic complaints often accompany it:

• Color vision deficits – especially in ischemic optic neuropathies.
• Pupillary abnormalities – a relative afferent pupillary defect (RAPD) in the affected eye.
• Pain on eye movement – typical of optic neuritis.
• Headache or scalp tenderness – a red flag for giant cell arteritis.
• Transient visual obscurations – may suggest papilledema.
• Systemic symptoms – fever, weight loss, jaw claudication, or polymyalgia rheumatica in vasculitic causes.
• Visual phenomena – such as flashing lights (photopsia) or floaters if a retinal vascular event is involved.

When to See a Doctor

Because altitudinal loss can herald an acute vascular or inflammatory event, timely evaluation is critical. Seek ophthalmic or emergency care promptly if you notice any of the following:

• Sudden onset of loss affecting the top or bottom half of the visual field in one eye.
• Accompanying eye pain, especially with movement.
• New headaches, especially scalp tenderness or jaw pain.
• Rapid progression of vision loss over minutes to hours.
• Associated systemic symptoms such as fever, unexplained weight loss, or muscle aches.

Even if the loss seems partial or improves, an urgent eye exam is warranted, as many causes can cause permanent damage if treatment is delayed.

Diagnosis

Diagnosing the cause of altitudinal loss involves a stepwise approach that combines a detailed history, clinical examination, and targeted investigations.

1. Clinical History and Physical Exam

• Onset, duration, and progression of visual change.
• Risk factors: hypertension, diabetes, hyperlipidemia, smoking, recent infections, or autoimmune disease.
• Medication review – especially anticoagulants or steroids.
• Comprehensive eye exam: visual acuity, color vision (Ishihara plates), pupillary response, intra‑ocular pressure, and slit‑lamp inspection of the anterior segment.
• Fundus examination – looking for disc edema, pallor, flame‑shaped hemorrhages, or retinal artery occlusion.

2. Visual Field Testing

Automated perimetry (e.g., Humphrey 24‑2) is the gold standard to map the defect and confirm an altitudinal pattern. Static or kinetic testing can also be used in patients unable to cooperate with full automated protocols.

3. Imaging Studies

• Optical Coherence Tomography (OCT) – assesses retinal nerve fiber layer (RNFL) thickness and can detect early optic nerve edema.
• Fundus Fluorescein Angiography (FFA) – visualizes retinal vascular perfusion, useful in artery occlusions.
• Magnetic Resonance Imaging (MRI) of the brain and orbits – rules out compressive lesions, demyelinating disease, or posterior circulation stroke.
• Orbital or cranial CT – preferred if a bony lesion or acute hemorrhage is suspected.

4. Laboratory Tests

• Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – essential to exclude giant cell arteritis.
• Complete blood count, metabolic panel, and lipid profile – evaluate vascular risk.
• Autoimmune panel (ANA, ANCA, antiphospholipid antibodies) – when systemic vasculitis is suspected.
• Coagulation studies – if a hypercoagulable state is considered.

5. Specialized Tests

In select cases, visual evoked potentials (VEP) can help differentiate demyelinating optic neuritis from ischemic causes.

Treatment Options

Treatment is directed at the underlying etiology. Early therapy can preserve vision and reduce the risk of recurrence.

1. Ischemic Optic Neuropathy (NA‑AION)

• Control vascular risk factors: aggressive blood pressure control, lipid‑lowering therapy (statins), smoking cessation, and glycemic management.
• No proven acute pharmacologic therapy for NA‑AION, but some clinicians consider short‑term high‑dose steroids, although evidence is limited (Cochrane Review 2021).

2. Arteritic AION (Giant Cell Arteritis)

• High‑dose intravenous methylprednisolone (500–1000 mg daily for 3 days) followed by oral prednisone 1 mg/kg.
• Prompt initiation is crucial—delayed treatment raises the risk of permanent blindness in the fellow eye.
• Long‑term low‑dose steroids with tapering, guided by ESR/CRP, and adjunctive methotrexate or tocilizumab in steroid‑sparing protocols.

3. Optic Nerve Sheath Meningioma or Glioma

• Surgical resection or radiosurgery for meningioma when vision deteriorates.
• Observation for small, asymptomatic gliomas; chemotherapy (e.g., carboplatin‑vincristine) for progressive cases.

4. Retinal Vascular Occlusion

• Immediate ocular massage, reduction of intra‑ocular pressure (acetazolamide, topical β‑blockers), and hyper‑oxygen therapy within the first 90 minutes.
• Systemic work‑up for embolic sources (carotid duplex, cardiac echo) and anticoagulation if a cardio‑embolic source is identified.

5. Optic Neuritis

• IV methylprednisolone 1 g/day for 3 days followed by oral taper; beneficial for visual recovery speed but modest impact on final visual acuity (ONTT, 2006).
• Consider disease‑modifying therapy for multiple sclerosis if MRI is positive.

6. Traumatic Optic Neuropathy

• High‑dose steroids (e.g., methylprednisolone 1 g daily for 3 days) are controversial; some suggest observation.
• Surgical decompression is reserved for optic canal fractures with progressive deficit.

7. Supportive & Home Measures

• Use of low‑vision aids (magnifiers, high‑contrast reading glasses) while awaiting definitive treatment.
• Regular follow‑up with an ophthalmologist/ neuro‑ophthalmologist to monitor visual field changes.
• Education on blood pressure self‑monitoring and lifestyle modifications.

Prevention Tips

While some causes (e.g., giant cell arteritis) cannot be prevented, many risk factors are modifiable:

• Maintain optimal cardiovascular health – blood pressure < 130/80 mmHg, LDL < 70 mg/dL for high‑risk patients, regular aerobic exercise.
• Control diabetes – HbA1c < 7 % reduces microvascular complications.
• Quit smoking – nicotine accelerates atherosclerosis and impairs optic nerve perfusion.
• Regular eye examinations – especially for individuals over 50, those with hypertension, or a family history of glaucoma.
• Prompt treatment of systemic infections – to lower the risk of secondary vasculitis.
• Annual flu and pneumococcal vaccinations – reduce systemic inflammation that can exacerbate vascular disease.
• Take prescribed antiplatelet or anticoagulant therapy as directed if you have known cardiovascular disease.

Emergency Warning Signs

Key Take‑aways

• Altitudinal visual loss is a distinct half‑field defect that signals potential optic nerve or retinal vascular compromise.
• Non‑arteritic AION is the most common cause, but arteritic AION, compressive tumors, stroke, and retinal occlusions are critical differentials.
• Early identification, a thorough neuro‑ophthalmic work‑up, and treatment of the underlying cause can preserve vision.
• Control of vascular risk factors and timely evaluation of systemic symptoms are the cornerstones of prevention.

For personalized advice, always discuss your symptoms with an eye‑care professional or neurologist. The information above reflects current guidelines from reputable sources such as the Mayo Clinic, CDC, NIH, WHO, and peer‑reviewed ophthalmology journals (2022‑2024).

```